SAT0342 Treatment of postmenopausal women with osteoporosis for six years with denosumab: Three-year results from the freedom extension

Roland Chapurlat ,Man Zhang ,H Resch ,Socrates E Papapoulos ,Maria Luisa Brandi ,J Román ,Rachel B Wagman ,Jacques P Brown ,Sebastião Cézar Radominski ,Dan Mellström ,Nathalie Franchimont ,Kui Ma ,Michelle Geller ,Steven R Cummings ,Susan Y Smith ,E J Czerwiński ,Nadia Daizadeh ,Jean‐Yves Reginster ,Christian Roux ,Henry G Bone

doi:10.1136/annrheumdis-2012-eular.3288

SAT0342 Treatment of postmenopausal women with osteoporosis for six years with denosumab: Three-year results from the freedom extension

Roland Chapurlat , Man Zhang + Show 18 more

https://doi.org/10.1136/annrheumdis-2012-eular.3288

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2013
Citations: 1

Affiliation: Inserm, Claude Bernard University Lyon 1, Leiden University Medical Center, University of Florence, Hospital Universitari i Politècnic La Fe, Amgen (United States), Centre hospitalier de l'Université Laval, Université Laval, Federal University of Paraná, Sahlgrenska University Hospital, University Hospital of Lausanne, Krakow Cardiovascular Research Institute, University of Liège, Délégation Paris 5, Université Paris Cité

#Cross-over Group #Speakers Bureau + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundDenosumab (DMAb) is approved for the treatment of postmenopausal women with osteoporosis at increased risk for fracture. A favorable risk/benefit profile was demonstrated in the pivotal, 3-year FREEDOM trial.1 The...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.